The effect of remifentanil intranasal on hemodynamic changes induced by electroconvulsive therapy

Evaluation of the effect of different doses of remifentanil intranasal on hemodynamic changes induced by electroconvulsive therapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200825048515N20

Enrollment

Registered

2021-01-03

Start date

2021-01-04

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Electroshock therapy. Shock therapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

Interventions

Intervention 1: Intervention group 1: Prior to electroconvulsive therapy, patients receive remifentanil at a dose of 0.25 mg/kg intranasally in both nostrils. One minute after the intervention, anesth

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Aged over 18 years Candidates for electroconvulsive therapy for the first time Classified as ASA I based on American Society of Anesthesiologists Classification No fever Consent to participate in the study

Exclusion criteria

Exclusion criteria: Allergy to remifentanil History of nasal-related diseases that interfere with intranasal drug administration

Design outcomes

Primary

Measure	Time frame
Blood pressure. Timepoint: 1, 5, 10, and 20 minutes after the end of the convulsion. Method of measurement: Monitoring device.;Heart rate. Timepoint: 1, 5, 10, and 20 minutes after the end of the convulsion. Method of measurement: Monitoring device.;Oxygen saturation. Timepoint: 1, 5, 10, and 20 minutes after the end of the convulsion. Method of measurement: Monitoring device.;Duration of convulsion. Timepoint: 1, 5, 10, and 20 minutes after the end of the convulsion. Method of measurement: Monitoring device.	—

Measure

Time frame

Blood pressure. Timepoint: 1, 5, 10, and 20 minutes after the end of the convulsion. Method of measurement: Monitoring device.;Heart rate. Timepoint: 1, 5, 10, and 20 minutes after the end of the convulsion. Method of measurement: Monitoring device.;Oxygen saturation. Timepoint: 1, 5, 10, and 20 minutes after the end of the convulsion. Method of measurement: Monitoring device.;Duration of convulsion. Timepoint: 1, 5, 10, and 20 minutes after the end of the convulsion. Method of measurement: Monitoring device.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehzad Nazemroaya

Esfahan University of Medical Sciences

behzad_nazem@med.mui.ac.ir+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026